Information  X 
Enter a valid email address

Medgenics Inc (MEDG)

  Print   

Wednesday 18 December, 2013

Medgenics Inc

Purchase of Common Stock by Director

RNS Number : 8468V
Medgenics Inc
18 December 2013
 



 

 

Press Release

18 December 2013

 

 

Medgenics Reports Open Market Purchase of Common Stock by Director

 

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), ("the Company"), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company, that he purchased 4,500 shares of common stock on the open market on 16 December at an average price of $5.7787 per share.

 

Following this purchase, Dr. Clemow now owns 18,500 shares of common stock, which represents approximately 0.1 per cent of the total issued shares of common stock.  Dr. Clemow also has the right to purchase up to 105,714 shares of common stock pursuant to options previously granted (in aggregate Dr. Clemow's shares of common stock and options represent 124,214 shares of common stock which represent approximately 0.7 per cent of the Company's total issued shares of common stock).

 

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

 

 

About Medgenics

 

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others.  For more information, please visit www.medgenics.com

 

 



Contacts:

 

Medgenics, Inc.

John Leaman, CFO

[email protected]

 

LHA

Anne Marie Fields

212-838-3777

[email protected]

@LHA_IR_PR

 


Abchurch Communications

Joanne Shears / Jamie Hooper / Harriet Rae

[email protected]

 

+44 207 398 7718

 

Oriel Securities (NOMAD & Broker)

Jonathan Senior / Giles Balleny

 

+44 207 710 7617 

 

 

 

- Ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANAPFEFDFEF

a d v e r t i s e m e n t